---
title: "NAMPT and NAD+ in Health and Disease: Molecular Roles and Therapeutic Challenges"
id: "pubmed-43067627"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-43067627"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/43067627/"
doi: "10.1186/s43556-026-00666-3"
published_at: "2026-11-22T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# NAMPT and NAD+ in Health and Disease: Molecular Roles and Therapeutic Challenges
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-43067627
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/43067627/)
- **DOI:** [10.1186/s43556-026-00666-3](https://doi.org/10.1186%2Fs43556-026-00666-3)
- **Published At:** 2026-11-22T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The review examines the central role of **NAMPT** as the rate-limiting enzyme in the **NAD+** salvage pathway and its control of cellular energy, redox balance, and NAD+-dependent enzymes. - Investigators described two forms: intracellular **iNAMPT**, which sustains NAD+ production and supports sirtuins, PARPs, and CD38 activity, and extracellular **eNAMPT**, implicated in interorgan signaling and inflammation. - The authors summarized NAD+ biosynthetic routes, noted subcellular compartmentalization and circadian regulation as determinants of pathway activity, and discussed NAPRT-dependent metabolic bypass as a modulator of NAD+ dependence. - Data indicated context-dependent effects: reduced NAMPT activity and NAD+ depletion associated with metabolic dysfunction, tissue injury, and neuronal vulnerability; conversely, elevated NAMPT activity can enhance tumor metabolic fitness and inflammatory responses. - Therapeutic approaches reviewed include NAD+ precursors, NAMPT activation, indirect modulators, and NAMPT inhibitors for oncology; each strategy carries specific translational constraints. - The authors identified key barriers to clinical translation: systemic NAD+ depletion, hematological and gastrointestinal toxicity, pharmacokinetic limitations, and tumor heterogeneity that complicates inhibitor efficacy. - Required next steps listed by the review: development of tissue-selective modulation, direct pharmacodynamic monitoring, and biomarker-guided patient selection for future trials.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/43067627/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43067627%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/43067627/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/43067627/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/43067627/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/43067627/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/43067627/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/43067627/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43067627%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43067627%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/43067627/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43067627/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43067627/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/43067627/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43067627/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/43067627/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/43067627/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/43067627/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/43067627/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/43067627/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/43067627/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/43067627/#substances) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/43067627/#grants) Title & authors Abstract Conflict of interest statement References Publication types MeSH terms Substances Grants and funding Review Mol Biomed Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mol+Biomed%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Mol+Biomed%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43067627/) . 2026 Nov 22;7(1):258. doi: 10.1186/s43556-026-00666-3. # NAMPT and NAD+ in health and disease: emerging perspectives from molecular mechanisms to therapeutic strategies [Lin Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+L&cauthor_id=43067627)[#](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-equal-contrib-explanation "Contributed equally")[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-affiliation-1 "Department of Hepatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Xiangmin Deng](https://pubmed.ncbi.nlm.nih.gov/?term=Deng+X&cauthor_id=43067627)[#](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-equal-contrib-explanation "Contributed equally")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Yi Su](https://pubmed.ncbi.nlm.nih.gov/?term=Su+Y&cauthor_id=43067627)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Chang Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+C&cauthor_id=43067627)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Yanqun Luo](https://pubmed.ncbi.nlm.nih.gov/?term=Luo+Y&cauthor_id=43067627)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Xiaoliang Deng](https://pubmed.ncbi.nlm.nih.gov/?term=Deng+X&cauthor_id=43067627)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Lei Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+L&cauthor_id=43067627)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-affiliation-3 "Department of Hepatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. et1978@126.com."), [Junming Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+J&cauthor_id=43067627)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-affiliation-4 "Minhang Hospital, Fudan University, Shanghai, 201199, China. chjm2008@126.com."), [Tao Wu](https://pubmed.ncbi.nlm.nih.gov/?term=Wu+T&cauthor_id=43067627)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#full-view-affiliation-5 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. tw827@shutcm.edu.cn.") Affiliations Expand ### Affiliations * 1 Department of Hepatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. * 2 Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. * 3 Department of Hepatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. et1978@126.com. * 4 Minhang Hospital, Fudan University, Shanghai, 201199, China. chjm2008@126.com. * 5 Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. tw827@shutcm.edu.cn. # Contributed equally. * PMID: **43067627** * DOI: [ 10.1186/s43556-026-00666-3 ](https://doi.org/10.1186/s43556-026-00666-3) Item in Clipboard Review # NAMPT and NAD+ in health and disease: emerging perspectives from molecular mechanisms to therapeutic strategies Lin Wang et al. Mol Biomed. 2026. Show details Display options Display options Format Abstract PubMed PMID Mol Biomed Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mol+Biomed%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Mol+Biomed%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43067627/) . 2026 Nov 22;7(1):258. doi: 10.1186/s43556-026-00666-3. ### Authors [Lin Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+L&cauthor_id=43067627)[#](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-equal-contrib-explanation "Contributed equally")[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-affiliation-1 "Department of Hepatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Xiangmin Deng](https://pubmed.ncbi.nlm.nih.gov/?term=Deng+X&cauthor_id=43067627)[#](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-equal-contrib-explanation "Contributed equally")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Yi Su](https://pubmed.ncbi.nlm.nih.gov/?term=Su+Y&cauthor_id=43067627)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Chang Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+C&cauthor_id=43067627)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Yanqun Luo](https://pubmed.ncbi.nlm.nih.gov/?term=Luo+Y&cauthor_id=43067627)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Xiaoliang Deng](https://pubmed.ncbi.nlm.nih.gov/?term=Deng+X&cauthor_id=43067627)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-affiliation-2 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China."), [Lei Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+L&cauthor_id=43067627)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-affiliation-3 "Department of Hepatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. et1978@126.com."), [Junming Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+J&cauthor_id=43067627)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-affiliation-4 "Minhang Hospital, Fudan University, Shanghai, 201199, China. chjm2008@126.com."), [Tao Wu](https://pubmed.ncbi.nlm.nih.gov/?term=Wu+T&cauthor_id=43067627)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43067627/#short-view-affiliation-5 "Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. tw827@shutcm.edu.cn.") ### Affiliations * 1 Department of Hepatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. * 2 Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. * 3 Department of Hepatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. et1978@126.com. * 4 Minhang Hospital, Fudan University, Shanghai, 201199, China. chjm2008@126.com. * 5 Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. tw827@shutcm.edu.cn. # Contributed equally. * PMID: **43067627** * DOI: [ 10.1186/s43556-026-00666-3 ](https://doi.org/10.1186/s43556-026-00666-3) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD⁺) salvage pathway and a key regulator of cellular energy metabolism, redox homeostasis, stress responses, and NAD⁺-dependent signaling. Through its intracellular form iNAMPT, NAMPT sustains NAD⁺ production and the activity of enzymes such as sirtuins, PARPs, and CD38; its extracellular form eNAMPT has also been implicated in interorgan communication and inflammatory signaling. Here, we review the molecular basis of the NAMPT-NAD⁺ axis, including NAD⁺ biosynthetic pathways, subcellular compartmentalization, circadian regulation, and the distinct proposed functions of iNAMPT and eNAMPT. We then evaluate its physiological and pathological roles in metabolic disorders, liver diseases, cancer, inflammatory and cardiovascular conditions, and neurodegenerative diseases. Current evidence supports a context-dependent role for NAMPT: reduced NAMPT activity and NAD⁺ depletion may contribute to metabolic dysfunction, tissue injury, and neuronal vulnerability, whereas elevated NAMPT activity can promote tumor metabolic fitness and inflammatory responses. However, NAMPT expression alone does not reliably indicate NAD⁺ pathway dependence, because outcomes are influenced by tissue context, disease stage, NAD⁺ consumption, precursor availability, and NAPRT-mediated metabolic bypass. Therapeutically, NAD⁺ precursors, NAMPT activation, and indirect modulators may be relevant in selected degenerative and metabolic settings, whereas NAMPT inhibitors remain under investigation for cancer. Their translation is limited by systemic NAD⁺ depletion, hematological and gastrointestinal toxicity, pharmacokinetic constraints, and tumor heterogeneity. Future progress will require tissue-selective modulation, direct pharmacodynamic monitoring, and biomarker-guided patient stratification. **Keywords:** Disease mechanisms; NAD⁺ metabolism; NAMPT; Precision medicine; Therapeutic targeting. © 2026. The Author(s). [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declarations. Ethics approval and consent to participate.: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest. ## References 1. 1. Houtkooper RH, Cantó C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010;31(2):194–223. . - [DOI](https://doi.org/10.1210/er.2009-0026) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/20007326/) 2. 1. Katsyuba E, Auwerx J. Modulating NAD+ metabolism, from bench to bedside. EMBO J. 2017;36(18):2670–83. . - [DOI](https://doi.org/10.15252/embj.201797135) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/28784597/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/5599801/) 3. 1. Revollo JR, Grimm AA, Imai SI. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754–63. . - [DOI](https://doi.org/10.1074/jbc.m408388200) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/15381699/) 4. 1. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14(2):1431–7. . - [DOI](https://doi.org/10.1128/mcb.14.2.1431-1437.1994) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/8289818/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/358498/) 5. 1. Garten A, Schuster S, Penke M, Gorski T, de Giorgis T, Kiess W. Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol. 2015;11(9):535–46. . - [DOI](https://doi.org/10.1038/nrendo.2015.117) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/26215259/) Show all 232 references ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43067627/) ## MeSH terms * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43067627/) * Cytokines* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cytokines%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cytokines) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43067627/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?t
## Related Clinical Research

- [MDK upregulation via WTAP/m6A/YTHDF1 promotes metastasis in clear cell renal cell carcinoma](https://medichelpline.com/clinical-feed/pubmed-43067604.md) (DOI: 10.1186/s43556-026-00665-4)
- [Eukaryotic pol ζ/Rev1 complex drives CG-to-GC transversions and large mutator effect](https://medichelpline.com/clinical-feed/biorxiv-1-minimal-eukaryotic-dna-polymerase-zeta-rev1-gc-pair-mutasome.md)
- [Sacituzumab tirumotecan versus physician's choice in previously treated endometrial cancer — phase](https://medichelpline.com/clinical-feed/pubmed-42933460.md) (DOI: 10.1016/S0140-6736(26)02099-4)
- [Early STAT+ Results for Alterome’s KRAS Inhibitor in Pancreatic, Lung, and Colorectal Cancer](https://medichelpline.com/clinical-feed/stat-news-1-stat-early-results-for-alterome-s-kras-drug-for-pancreas-lung-and-colon-cancer.md)
- [Circulating immune signatures during pembrolizumab-based neoadjuvant therapy in early triple-negat](https://medichelpline.com/clinical-feed/medrxiv-21-circulating-immune-dynamics-during-neoadjuvant-chemoimmunotherapy-in-early.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.